Marcus Q Bernardini
Overview
Explore the profile of Marcus Q Bernardini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
2138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gervais N, Gravelsins L, Brown A, Reuben R, Perovic M, Karkaby L, et al.
Front Endocrinol (Lausanne)
. 2023 Oct;
14:1265470.
PMID: 37859979
Introduction: Women with early ovarian removal (<48 years) have an elevated risk for both late-life Alzheimer's disease (AD) and insomnia, a modifiable risk factor. In early midlife, they also show...
12.
Piedimonte S, Kim R, Bernardini M, Atenafu E, Clark M, Lheureux S, et al.
Gynecol Oncol
. 2023 May;
167(3):417-422.
PMID: 37191644
Objective: The objective of this study is to externally validate the KELIM (rate of elimination of CA-125 elimation) score in patients with high grade serous ovarian cancer(HGSC)undergoing NACT and determine...
13.
Piedimonte S, Bernardini M, Ding A, Laframboise S, Ferguson S, Bouchard-Fortier G, et al.
Int J Gynecol Cancer
. 2023 Apr;
33(7):1077-1082.
PMID: 37015756
Background: We previously developed the Integrated Prediction Model using a 4-step algorithm of unresectable stage IVB, patient factors, surgical resectability, and surgical complexity to predict outcome of <1 cm cytoreduction...
14.
Millar D, Yang S, Sayad A, Zhao Q, Nguyen L, Warner K, et al.
Cancer Immunol Immunother
. 2023 Mar;
72(7):2375-2392.
PMID: 36943460
Immunotherapeutic strategies aimed at enhancing tumor cell killing by tumor-specific T cells hold great potential for reducing tumor burden and prolonging survival of cancer patients. Although many potential tumor antigens...
15.
Ren A, Filippou P, Soosaipillai A, Dimitrakopoulos L, Korbakis D, Leung F, et al.
Clin Chem Lab Med
. 2022 Nov;
61(3):464-472.
PMID: 36380677
Objectives: Ovarian cancer is the most lethal gynecological malignancy in developed countries. One of the key associations with the high mortality rate is diagnosis at late stages. This clinical limitation...
16.
Piedimonte S, Erdman L, So D, Bernardini M, Ferguson S, Laframboise S, et al.
J Surg Oncol
. 2022 Nov;
127(3):465-472.
PMID: 36350138
Objective: To develop a machine learning (ML) algorithm to predict outcome of primary cytoreductive surgery (PCS) in patients with advanced ovarian cancer (AOC) METHODS: This retrospective cohort study included patients...
17.
Piedimonte S, Bernardini M, Ding A, Laframboise S, Ferguson S, Bouchard-Fortier G, et al.
Gynecol Oncol
. 2022 Jul;
166(3):453-459.
PMID: 35820987
Objective: To report performance of an integrated predictive model (IPM) algorithm based on patient factors, surgical resectability and surgical complexity to predict outcome of primary cytoreductive surgery (PCS) and guide...
18.
Swift B, Covens A, Mintsopoulos V, Parra-Herran C, Bernardini M, Nofech-Mozes S, et al.
Int J Gynecol Cancer
. 2022 Jun;
32(10):1276-1282.
PMID: 35768155
Objective: To evaluate oncologic outcomes in patients with stage I endometrioid ovarian cancer treated with fertility-sparing compared with conventional surgery and to describe reproductive outcomes. Methods: A retrospective cohort study...
19.
Tinker A, Altman A, Bernardini M, Ghatage P, Gien L, Provencher D, et al.
Curr Oncol
. 2022 Jun;
29(6):4354-4369.
PMID: 35735457
The majority of patients with advanced, high-grade epithelial-tubo ovarian cancer (EOC) respond well to initial treatment with platinum-based chemotherapy; however, up to 80% of patients will experience a recurrence. Poly(ADP-ribose)...
20.
Devaud N, Vornicova O, Abdul Razak A, Khalili K, Demicco E, Mitric C, et al.
Surg Oncol Clin N Am
. 2022 Jun;
31(3):527-546.
PMID: 35715148
Leiomyosarcomas are soft tissue tumors that are derived from smooth muscle mainly in the pelvis and retroperitoneum. Percutaneous biopsy is paramount to confirm diagnosis. Imaging is necessary to complete clinical...